Background and study aims
Abstract
Background and study aims Screening programs for lung cancer may lead to a heightened awareness of the risks of smoking and enhance quitting. The aim of this study was to evaluate if the participation on a chemoprevention study for pre-malignant lesions, could influence smoking cessation.
Methods
Two hundred and one volunteers, current (n=188) and former smokers (n=13) with > 20 pack years, had been screened for the chemoprevention study. One hundred and forty-six of the current smokers at time of chemoprevention study screening have been retrospectively interviewed about their smoking behavior > 1 year after their first contact for the chemoprevention study. Structured questionnaires were used and interviews were held by telephone. The quitters at the time of these first interviews were contacted again 4 years after the initial interview, about their current smoking behavior.
Results
Of the 146 smoking volunteers, 83 were diagnosed with pre-malignant lesions of the bronchial mucosa and participated in the chemoprevention study, 63 had no pre-malignant lesions and were not included in that study. The majority of participants were male: 87 (60%). The mean age of the participants was 52±9 years, and the mean age at which volunteers started smoking was 15±3. Mean number of pack years was 47±27. Ten volunteers in the group without pre-malignant lesions and 19 in the group with premalignant lesions had quit smoking at time of the first interview. The smoking cessation rate of the total study group was 20%. Univariate logistic regression analysis demonstrated that smoking cessation was only significantly associated with male gender. No significant associations were found between smoking cessation and the finding of pre-malignant lesions, gender, age, level of addiction, educational level, marital condition, history of cancer/pulmonary diseases, age at start smoking, previous attempts to quit smoking and motivation to quit smoking. Within the group of subjects who had quit smoking at the time of the first interview, 15 out of 29 persons who had stopped smoking at the time of the first interview, have reported that participation in the bronchoscopy screening and/or the trial, has been of major influence on their decision to stop smoking.
Introduction
Smoking is a major causative factor of cardiovascular disease and the most important cause of lung cancer [1] [2] [3] . Ninety percent of lung cancer patients are (former) smokers 1 , and in Europe, Japan and North America, between 87 and 91% of lung cancers in men, and between 57 and 86% of lung cancers in women, are attributable to smoking [4] [5] [6] . Since cardiovascular diseases and lung cancer are among the most important causes of mortality in the western countries 7, 8 , reduction of the number of smokers would be of great benefit for public health. Smoking cessation is the best preventive measure for these smoking related diseases. However, despite the knowledge that smoking is a harmful habit, multiple messages on cigarette boxes, antismoking campaigns, scientists' and doctors' warnings [9] [10] [11] , there are still many smokers [12] [13] [14] , and only a small percentages of smokers succeed to quit permanently. Despite a minor reduction in the number of smokers during the last decade, still around 25% of the adult population smoked in the Netherlands in 2007 15 . Furthermore, smoking cessation has proven to be extremely difficult to achieve. Even with counseling and nicotine replacement therapy, the success rate remains low [16] [17] [18] . Another way to reduce smoking related mortality is secondary prevention, i.e. screening for smoking related diseases. Screening for lung cancer with different screening modalities aims at detecting the disease at an early stage, so that treatment may be more effective. Screening for early stage lung cancer may result in a high actuarial survival rate in selected volunteers 19 , but whether screening is truly effective still needs to be proven in (ongoing) randomized controlled trials 20 .
Screening programs for smoking related diseases may also lead to heightened awareness of the risks of smoking among participants and thus help reduce the number of smokers. On the other hand, it could be argued that smokers participating in a screening program are aware of the dangers of smoking and may get a false sense of security when results of screening do not demonstrate abnormalities, and cause them to lose their motivation to stop.
Some studies have shown that participants in CT screening programs quit smoking more often when abnormal findings (usually of unknown significance) were present. Cessation rates were high 21, 22 .
At the beginning of February 2002, a chemoprevention study was initiated at the VU University Medical Center (VUmc) and the Netherlands Cancer Institute (NKI) in Amsterdam, the Netherlands. Volunteers with at least 20 pack years of smoking were screened by bronchoscopy and when a premalignant lesion was present, enrolled in a double blind placebo-controlled phase II study 23 . The goal of present study is to evaluate whether participating in the above mentioned study and the knowledge of the presence of premalignant lesions enhanced cessation rate. We hypothesized that volunteers who underwent screening by bronchoscopy and participated to the trial because they had pre-malignant lesions, were more likely to quit smoking than volunteers who did not.
Materials and Methods

Subjects
Between February 2002 and October 2004, 201 current and former smokers were screened for a double blind randomized controlled trial (RCT) of the inhalation corticosteroid fluticasone diproprionate to study its effect on bronchoscopically detected premalignant lesions in the bronchial mucosa 23, 24 . Volunteers were recruited by repeated advertisement in (local) newspapers, information folders at the VUMC hospital and NKI hospital or asked by their pulmonary physician of the VUMC or NKI hospital whether they wanted to participate.
Inclusion criteria for this chemoprevention study were healthy volunteers, current or former smokers, with a smoking history of over 20 pack years. Patients who had undergone treatment with curative intent of head and neck-or lung cancer of any stage and did not show any sign of recurrence on computer tomography (CT) were also asked to participate. Exclusion criteria were serious co-morbid disease, FEV1 values below 1000 ml or use of systemic or inhaled corticosteroids in the year prior to enrolment.
The inclusion criteria of present study were as follows: all volunteers who were screened by bronchoscopy for the above mentioned trial and smoked at the time of screening (t0). Exclusion criteria were also formulated: former smokers at t0 were excluded, since their decision to quit smoking was taken before their response to participate in the chemoprevention study. Volunteers who fulfilled inclusion criteria according to our data but appeared not to have undergone any bronchoscopy were excluded as well (see figure 1: Flow Chart).
At least 1 year after the initial contact for screening for the fluticasone study (mean time period between initial contact and first interview was 21±7 months, time period of this contact for first interviews abbreviated as t1), we approached all persons who had undergone bronchoscopy and participated in the RCT, as well as those who had undergone bronchoscopy but were not eligible for the chemoprevention trial because they had no pre-malignant lesions.
These volunteers received a letter from our institution and were approached by phone at least one week later. When the volunteers were reached by telephone, they were first asked if they had received the letter announcing present study in continuation of the previous one. If not, explanation about the present study was given and volunteers were asked to participate. If they had received the letter, they would immediately be asked to participate. The volunteers were retrospectively interviewed by phone using standardized questionnaires regarding several issues including their smoking status. Usually the interviews took place at the first telephone contact. *No intervention: volunteers had received information only and were neither screened by bronchoscopy nor included in the trial t0 is the time of screening for the Fluticasone study, time at which volunteers had neither started yet with investigations nor had undergone any bronchoscopy. t1 is the time of the first interviews and t2 the time of the second interviews Around 4 years after the initial contact for screening for the fluticasone study (mean time period between initial contact and second interview was: 54±8 months), we approached once again, following the same strategy as mentioned previously, volunteers who were former smokers at t1, for a second retrospective, structured interviews by telephone regarding their present smoking status (at present time period, contact for second interviews, abbreviated as t2).
Interviews
The first interviews took place by telephone by BBMP and RMS, in the period of June 2005 until February 2006 (t1). The questionnaire contained 35 open or multiple choice questions and statements concerning demographic data, level of education, medical history, motivation to participate in the fluticasone trial, smoking history, smoking behavior and subjective experience of burden by bronchoscopy (scale from 1 until 10, with 1: no burden at all, and 10: great burden).
Concerning their smoking behavior participants were asked: "Do you smoke at the moment?" If they answered "yes" they were asked, "How many cigarettes do you smoke in a day?" If "no" they were asked "To what extent did volunteering and/or participating in the fluticasone study make you quit smoking?" Participants could answer 1) not at all, 2) to some extent, or 3) to a major extent.
The second interviews with former smokers at t1 took place by telephone by RMS from June 2008 until August 2008 (t2), with a set of 7 questions derived from the first questionnaire to assess their smoking behavior once again and the influence of the Fluticasone trial on their decision to quit smoking and to keep refraining from smoking.
Data on smoking cessation was based only on participants' answers to the interview questions.
Statistical Analysis
We performed descriptive analyses and we used χ2-tests and independent t-tests to identify differences in demographics between our study groups.
Regression analysis was performed to analyze which factors were associated with smoking cessation.
All analyses were conducted using SPSS version 15.0.
Results
Participant characteristics
Data of the 201 volunteers who had been screened for the chemoprevention study were at our disposal. Eleven subjects could not be reached, 8 did not give their consent for the interviews, and 36 were excluded because they were former smokers at t0 and/or appeared to have not undergone any kind of intervention (bronchoscopy/trial participation). Ultimately, we interviewed 146 subjects for this smoking behavior study (see figure 1: Flow Chart) . The study participants have been divided into 2 groups (table 1).
Group 1 consisted of 63 subjects who were excluded from the RCT because they had no pre-malignant endobronchial lesions found at bronchoscopy, and group 2 consisted of 83 subjects who had participated in RCT because they fulfilled all inclusion criteria including the presence of premalignant endobronchial lesions. The majority of participants were male: 87 (60%). There were significantly more males in the group with pre-malignant lesions. There were no significant differences in history of malignancies between the group with (n=11) and the group without pre-malignant lesions (n=4). The mean age of all participants was 52±9 years, and the mean age at which subjects started smoking was 15±3. Mean number of pack years was 47±27. At time of the 1st interview (t1), the mean number of cigarettes smoked per subject was 22±13/ day, which is less than at time of screening for the fluticasone study t0 (27±13/ day). The number of pack years and the number of cigarettes smoked per day at t0 was significantly higher in the group with pre-malignant lesions. c. In the group without premalignant lesions, no volunteer had suffered from smoking related cancers (lung and head and neck cancer) and four from other cancer types (one lymphoma, one skin, and two breast cancers). In the group with premalignant lesions, four volunteers had suffered from head and neck cancer and seven from other cancer types (one lymphoma, two testis, one skin, two breast cancers, and one unknown). d. t0 is the time of screening for the Fluticasone study, time at which volunteers had neither started yet with investigations nor had undergone any bronchoscopy. t1 is the time of the first interviews and t2 the time of the second interviews.
e. Group without premalignant lesions: n = 53 and group with premalignant lesions: n = 64, total: n = 117. f. Experienced burden of bronchoscopy: 1 = no burden at all and 10 = great burden.In the group with premalignant lesions (n = 62), one patient could not remember his/her experienced burden of bronchoscopy because of brain damage due to epilepsy. COPD, chronic obstructive pulmonary disease; NKI, Netherlands Cancer Institute; VUMC, VU University Medical Center; SD, standard deviation.
Smoking cessation
At the time of the first interview (t1), 10 subjects in the group without pre-malignant lesions and 19 in the group with pre-malignant lesions had quit smoking. The smoking cessation rates are respectively 16% and 23%. The smoking cessation rate of the total study group was 20%.
Smoking cessation factors
Univariate logistic regression analysis (table 2) demonstrated that smoking cessation was only significantly associated with male gender. Number of attempts to quit smoking in the past tended to show an association with smoking cessation, but did not reach significance. 
Bronchoscopy
Volunteers who underwent at least one bronchoscopy were asked to grade their subjective experience on a scale from 1 until 10 (with 1: no burden at all, and 10: great burden). Mean subjective experience in the group of former smokers at time of first interview was 6.0±2.2 and in the current smokers 6.0± 2.5. Mean subjective experience in group 1 (n=62, 1 person could not remember her experience with bronchoscopy) was 6.0±2.6 and 6.2±2.4 in group 2 (n=83). Independent t-tests did not show any significant difference between participant groups and between former smokers and current smokers at time of the first interviews.
Opinions about trial influence
Within the group of subjects who had quit smoking at t1, 15 out of 29 subjects have reported screening with bronchoscopy and/or trial participation of a major influence on their decision for smoking cessation. One subject answered "do not know", 9 answered "no influence" and 4 "some influence". Among participants who had pre-malignant lesions, 74% (14 out of 19) considered participation in the trial as a major influence on their smoking behavior. The reported trial influence (n=28) (influence or no influence) on smoking cessation and the fact of having pre-malignant lesions or not, tended to show a relationship but did not reach significance with a chi-square test (p=0.097) (table 3).
Second interviews (t2)
Of the 29 subjects who were former smokers at the time of the first interview (t1), 26 subjects were interviewed again (see figure 1: Flow Chart). One subject could not be reached and 2 subjects had died (causes of death: car accident and metastasized posterior tongue carcinoma).
Of the subjects participating in the second interview (n=26), 19 (73%) (still) did not smoke at time of the second interview t2, this is 13% of our total study population, and gives smoking cessation rates of 11% for the group without pre-malignant lesions and 14% for the group with pre-malignant lesions. Three of the "refrainers" had resumed smoking after a period of abstinence following trial participation, but had quit again at t2. Of the total group of former smokers at t1(n=26), 16 (62%) still considered the trial as an influencing factor on their smoking behavior. A chi-square test between the reported trial influence (influence vs. no influence) and the fact of having pre-malignant lesions or not, showed a significant relationship at t2 (p=0.046), p<0.05.
Trial influence Yes (N) (%)
Quitters after t0 at t1 
Discussion
This quitting rate of 20% among volunteers for a chemo-preventive trial after almost 2 years since initial contact was higher than what is normally found after active smoking campaigns among the general population 14, 25 -although we must emphasize that we are looking at a selected study group and comparable to what was found in other studies aimed at screening for lung cancer by the use of Computed Tomography Scan Screening: Townsend et al 24-42% and Ostroff et al 23% 21, 22 . There seemed to be an association between trial participation and smoking cessation since volunteers included in the trial showed a higher smoking cessation rate than volunteers excluded. The distinguishing factor between these 2 groups and determinant of trial inclusion was the finding of premalignant lesions at bronchoscopy. Since other studies had shown that having smoking related diseases, experiencing smoking related symptoms or having smoking related damage resulted in higher smoking cessation rates [26] [27] [28] , we assumed that the supposed association between smoking cessation and the presence of pre-malignant lesions was reliable. However, this association was not statistically significant. Of all known factors related with smoking cessation only male gender was significant 27, 29 . There was a trend of higher cessation rates if pre-malignant lesions were found, which is contrary to what one might expect as the level of addiction (indicated with pack years and number of cigarettes smoked per day) is associated with smoking behavior [29] [30] [31] and differed significantly in both groups at baseline. Other factors such as level of interest in quitting smoking, age of starting smoking, age of participant, education, marital status, history of cancer or lung diseases and previous attempts to quit smoking 25, 27, [29] [30] [31] were not significant. Small sample size might play an important role in these findings. We may be confronted with a low statistical power as a consequence of the retrospective study design. Knowing that an initially strong motivation to quit smoking disappears quickly 32 (32) , even in patients being diagnosed with cancer, one might expect that having pre-malignant lesions is not likely to be a very strong motivation to stop. Because of its invasive character and reported patients' anxiety, fear of pain and breathing difficulties during bronchoscopy 33 , as well as the fear for cancer diagnosis following the diagnostic intervention 34 , we expected that the experience of bronchoscopy would affect a patient's smoking habits. However, it is unlikely that the (unpleasant) experience of a bronchoscopy as a single factor is associated to quitting smoking in present study, since we have found no significant difference between the subjective burden of a bronchoscopy between former smokers at t1 and volunteers who never quit smoking. Smit et al. 35 and Scholte op Reim et al. 36 , also found that despite a major smoking related event, such as a pneumothorax or an acute myocardial infarction, many people continue to smoke. Our study also has other limitations beside the number of participants. First, our results are based upon participants' answers. Participants may have given more socially acceptable answers about their smoking behavior out of shame for their addiction. Furthermore, we did not determine criteria to define the "former smoker" in unit of time (e.g. volunteers are classified as former smoker if they have refrained from smoking during 3 months). We can thus only trust participants' answers and consider them as former smokers if they have said so. Also, we only have contacted the volunteers who were former smokers at time of the first interview (t1) twice. "Current smokers" at t1 have been contacted just once. As the smoking behavior of the smokers at time of first interviews is unknown for the second interviews, an underestimation of the smoking cessation is possible, although it seems improbable that smokers at t1 would have quit smoking at t2, considering that smoking cessation is very difficult to achieve despite motivation 37 . Fortunately, there is no indication that reassurance (informing a subject that no abnormalities were found), leads to more dangerous behavior (i.e. smoking). Participants of the group without premalignant lesions smoked less at t1 than at trial screening time (t0). The drop in persistent quitters between t1 and t2 confirms the need for prolonged support to prevent relapse.
Conclusions
We found a smoking cessation rate of 20% among volunteers for a chemo-prevention trial investigating smoking related pre-malignant lesions almost 2 years after initial contact. Volunteers experienced screening and trial participation as influencing smoking cessation. Smoking cessation was significantly associated with male gender while the finding of premalignant lesions by bronchoscopy was not.
